Form 13-F position report

SILVERBACK THERAPEUTICS INC

Reported by MORGAN STANLEY

SPRY CUSIP 82835W108 Manager CIK 0000895421

Reported 237,338 shares, down 148,340 (38.5%) from the prior quarter.

Reported value -25.6%; share count -38.5% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 237,338 Quarter-end amount reported
Reported value $1,007,000 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 9263000
2022-03-31 1354000
2022-06-30 1007000
2022-09-30 295000
2022-12-31 760996
2023-03-31 648436
2023-06-30 406549
2023-09-30 318326
2023-12-31 591364
2024-03-31 1001080
2024-06-30 1138688
2024-09-30 9260021
2024-12-31 4563963
2025-03-31 5566825
2025-06-30 6694106
2025-09-30 7039160
2025-12-31 6435049
2026-03-31 2542884
2026-06-30 1835091
2026-09-30 1614965

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for SILVERBACK THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 374,702 +145,602 (63.6%) < 0.01% $1,614,965 2026-11-13
Q2 2026 Reduced 229,100 -87,573 (-27.7%) < 0.01% $1,835,091 2026-08-13
Q1 2026 Reduced 316,673 -235,691 (-42.7%) < 0.01% $2,542,884 2026-05-15
Q4 2025 Reduced 552,364 -148,050 (-21.1%) < 0.01% $6,435,049 2026-02-13
Q3 2025 Added 700,414 +316,798 (82.6%) < 0.01% $7,039,160 2025-11-14
Q2 2025 Reduced 383,616 -58,898 (-13.3%) < 0.01% $6,694,106 2025-08-15
Q1 2025 Added 442,514 +9,911 (2.3%) < 0.01% $5,566,825 2025-05-15
Q4 2024 Reduced 432,603 -206,019 (-32.3%) < 0.01% $4,563,963 2025-02-14
Q3 2024 Added 638,622 +504,816 (377.3%) < 0.01% $9,260,021 2024-11-14
Q2 2024 Added 133,806 +35,853 (36.6%) < 0.01% $1,138,688 2024-08-14
Q1 2024 Reduced 97,953 -9,960 (-9.2%) < 0.01% $1,001,080 2024-05-15
Q4 2023 Added 107,913 +23,700 (28.1%) < 0.01% $591,364 2024-02-13
Q3 2023 Added 84,213 +23,534 (38.8%) < 0.01% $318,326 2023-11-15
Q2 2023 Reduced 60,679 -38,927 (-39.1%) < 0.01% $406,549 2023-08-14
Q1 2023 Added 99,606 +10,392 (11.6%) < 0.01% $648,436 2023-05-15
Q4 2022 Added 89,214 +33,119 (59.0%) < 0.01% $760,996 2023-02-14
Q3 2022 Reduced 56,095 -181,243 (-76.4%) < 0.01% $295,000 2022-11-14
Q2 2022 Reduced 237,338 -148,340 (-38.5%) < 0.01% $1,007,000 2022-08-15
Q1 2022 Reduced 385,678 -1,005,232 (-72.3%) < 0.01% $1,354,000 2022-05-13
Q4 2021 Added 1,390,910 +752,209 (117.8%) < 0.01% $9,263,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

86 managers reported SILVERBACK THERAPEUTICS INC for Q2 2022.

Managers reporting SILVERBACK THERAPEUTICS INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 8,740,887 0 0.68% $37,061,000 7 qtrs
FMR LLC Reduced 3,718,452 -74,720 < 0.01% $15,766,235 7 qtrs
Nextech Invest Ltd Unchanged 1,910,029 0 2.73% $8,099,000 3 qtrs
K2 PRINCIPAL FUND L P New 1,541,706 +1,541,706 0.72% $6,537,000 1 qtr
Nantahala Capital Management LLC Added 1,386,138 +472,541 0.29% $5,877,000 7 qtrs
VANGUARD GROUP INC Added 1,056,664 +233,368 < 0.01% $4,480,000 7 qtrs
Rubric Capital Management LP New 986,453 +986,453 0.22% $4,183,000 1 qtr
BlackRock Inc Reduced 707,845 -899,396 < 0.01% $3,001,000 7 qtrs
EcoR1 Capital LLC Added 575,359 +245,822 0.08% $2,440,000 7 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 549,299 -121,243 < 0.01% $2,329,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
236,217
Shared
0
None
1,121

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.